4.8 Article

VARIDT 2.0: structural variability of drug transporter

Journal

NUCLEIC ACIDS RESEARCH
Volume 50, Issue D1, Pages D1417-D1431

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/nar/gkab1013

Keywords

-

Funding

  1. Natural Science Foundation of Zhejiang Province [LR21H300001]
  2. National Natural Science Foundation of China [81973394, 81872798, U1909208]
  3. Leading Talent of the 'Ten Thousand Plan'-National High-Level Talents Special Support Plan of China
  4. Fundamental Research Fund for Central Universities [2018QNA7023]
  5. 'Double Top-Class' University Project [181201*194232101]
  6. Key R&D Program of Zhejiang Province [2020C03010]
  7. Westlake Laboratory (Westlake Laboratory of Life Sciences and Biomedicine)
  8. Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare
  9. Alibaba Cloud
  10. Information Technology Center of Zhejiang University

Ask authors/readers for more resources

This study describes a major update of the VARIDT database, including experimental resolved structures and structural variability data updates through literature review and homology modeling. The newly collected data are essential for explaining drug sensitivity, revealing drug-drug interaction mechanisms, and more.
The structural variability data of drug transporter (DT) are key for research on precision medicine and rational drug use. However, these valuable data are not sufficiently covered by the available databases. In this study, a major update of VARIDT (a database previously constructed to provide DTs' variability data) was thus described. First, the experimentally resolved structures of all DTs reported in the original VARIDT were discovered from PubMed and Protein Data Bank. Second, the structural variability data of each DT were collected by literature review, which included: (a) mutation-induced spatial variations in folded state, (b) difference among DT structures of human and model organisms, (c) outward/inward-facing DT conformations and (d) xenobiotics-driven alterations in the 3D complexes. Third, for those DTs without experimentally resolved structural variabilities, homology modeling was further applied as well-established protocol to enrich such valuable data. As a result, 145 mutation-induced spatial variations of 42 DTs, 1622 inter-species structures originating from 292 DTs, 118 outward/inward-facing conformations belonging to 59 DTs, and 822 xenobiotics-regulated structures in complex with 57 DTs were updated to VARIDT (https://idrblab.org/varidt/ and http://varidt.idrblab.net/). All in all, the newly collected structural variabilities will be indispensable for explaining drug sensitivity/selectivity, bridging preclinical research with clinical trial, revealing the mechanism underlying drug-drug interaction, and so on.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available